

Swiss drug maker Roche posts flat 3Q sales

October 16 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

The Basel, Switzerland-based company says group [sales](#) were 34.8 billion Swiss francs, nearly unchanged from 34.9 billion francs in the same time period last year. But when measured in constant exchange rates, sales rose 5 percent over the first three quarters of the year.

It notes that a number of currencies, notably the U.S. dollar, remained weaker against the Swiss franc throughout the year.

The world's biggest producer of cancer-fighting drugs said Thursday that sales of cancer medicines Herceptin, Perjeta and Kadcylla together increased 21 percent, while its sales of rheumatoid arthritis treatment Actemra/RoActemra rose 24 percent.

© 2014 The Associated Press. All rights reserved.

Citation: Swiss drug maker Roche posts flat 3Q sales (2014, October 16) retrieved 6 May 2024 from <https://medicalxpress.com/news/2014-10-swiss-drug-maker-roche-flat.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--